Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aerosolized Moli1901 dose-finding study in adolescents and adults with cystic fibrosis
2006-006693-24Phase 2Completed
- Sponsor
- AOP Health
- Start
- Jan 2007
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of Lancovutide in cystic fibrosis (CF) (4 arms), sponsored by AOP Health. Primary endpoint: Change in percent predicted FEV1. Started Jan 2007; status: completed.
02
Drugs
Lancovutide
03
Conditions
cystic fibrosis (CF)
Beyond the preview
Go deeper on 2006-006693-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-006693-24.